No Data
Galapagos Downgraded to Reduce From Hold at Kepler Cheuvreux
Galapagos to Present Data on CAR T-cell Therapy Candidates GLPG5101 and GLPG5201
Galapagos to Present Results of Pioneering Innovation in Cancer Cell Therapy at ASH 2024
Analysts' Opinions Are Mixed on These Healthcare Stocks: Haleon PLC Sponsored ADR (HLN), Insmed (INSM) and Galapagos (GLPG)
Morgan Stanley Maintains Galapagos(GLPG.US) With Hold Rating, Maintains Target Price $31
Galapagos Third Quarter 2024 Earnings: €0.74 Loss per Share (Vs €0.39 Profit in 3Q 2023)
whqqq : Thank you for your comprehensive sharing